gemfibrozil has been researched along with Arteriosclerosis in 39 studies
Arteriosclerosis: Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designed to determine the effect of a 3 month treatment with Gemfibrozil (GF) on flow-mediated vasodilatation and insulin sensitivity." | 9.09 | Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. ( Avogaro, A; de Kreutzenberg, S; Del Prato, S; Favaro, A; Gottardo, L; Manzato, E; Miola, M; Pacini, G; Piliego, T; Sacerdoti, D; Tiengo, A; Zambon, S, 2001) |
| "This study was designed to determine the effect of a 3 month treatment with Gemfibrozil (GF) on flow-mediated vasodilatation and insulin sensitivity." | 5.09 | Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. ( Avogaro, A; de Kreutzenberg, S; Del Prato, S; Favaro, A; Gottardo, L; Manzato, E; Miola, M; Pacini, G; Piliego, T; Sacerdoti, D; Tiengo, A; Zambon, S, 2001) |
| " In this study, the area under the curve, maximum plasma concentration, and time to maximum concentration for fluvastatin and gemfibrozil are compared, when used alone and in combination, in patients with hyperlipidemia and either coronary or carotid atherosclerosis, or a family history of coronary artery disease." | 5.08 | Pharmacokinetics of the combination of fluvastatin and gemfibrozil. ( Hendricks, L; Khouri, HE; Latchinian, L; Munoz, CE; Spence, JD, 1995) |
| "Gemfibrozil is an effective and safe drug in patients with coronary heart disease (CHD) and the high triglyceride-low HDL cholesterol trait." | 2.67 | Gemfibrozil treatment of the high triglyceride-low high-density lipoprotein cholesterol trait in men with established atherosclerosis. ( Kastelein, JJ; Knipscheer, HC; Mulder, WJ; Nurmohamed, MT; Plaat, B; Pruijs, HJ; Van den Ende, A, 1994) |
| "Gemfibrozil was given to 10 patients with evidence of severe atherosclerosis; four similar patients acted as controls." | 2.65 | A pilot study of the effect of Gemfibrozil on some haematological parameters. ( Adams, CM; Etherington, MD; Goodland, FC; Middleton, JE; O'Brien, JR; Shuttleworth, RD, 1982) |
| "The metabolic syndrome is characterized by atherogenic dyslipidemia (elevated triglycerides, increased small dense low-density lipoproteins, and decreased high-density lipoproteins), hypertension, insulin resistance and obesity." | 2.41 | Treatment of dyslipoproteinemia in the metabolic syndrome. ( Fenselau, S; Schrezenmeir, J; Steinmetz, A, 2001) |
| "Gemfibrozil has been shown to have beneficial effects in the primary and secondary prevention of atherosclerosis." | 1.31 | Effect of gemfibrozil on peripheral atherosclerosis and platelet activation in a pig model of hyperlipidemia. ( Alfón, J; Badimon, L; Berrozpe, M; Royo, T, 2000) |
| "A decision to treat hyperlipidemias would be based on the assumption that such disorders lead to accelerated atherogenesis and ultimately to cardiac dysfunction." | 1.30 | Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation. ( Kesten, S; Maurer, J; Mayne, L; Scavuzzo, M, 1997) |
| "Terbutaline has also been reported to raise HDL cholesterol." | 1.27 | Nonpharmacologic and pharmacologic alteration of high-density lipoprotein cholesterol: therapeutic approaches to prevention of atherosclerosis. ( Glueck, CJ, 1985) |
| "Probucol has a sustained effect, additive to that of a lipid-lowering diet; it can reduce total serum cholesterol and cause xanthoma regression even in patients with receptor-defective homozygous familial hypercholesterolemia." | 1.27 | Medical management of hyperlipidemia and the role of probucol. ( Davignon, J, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (20.51) | 18.7374 |
| 1990's | 17 (43.59) | 18.2507 |
| 2000's | 14 (35.90) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Talmud, PJ | 2 |
| Martin, S | 1 |
| Taskinen, MR | 4 |
| Frick, MH | 3 |
| Nieminen, MS | 3 |
| Kesäniemi, YA | 3 |
| Pasternack, A | 3 |
| Humphries, SE | 2 |
| Syvänne, M | 4 |
| Tavintharan, S | 1 |
| Lim, SC | 1 |
| Sum, CF | 1 |
| Segarra Domènech, J | 1 |
| Santafé Oroz, J | 1 |
| O'Brien, JR | 1 |
| Etherington, MD | 1 |
| Shuttleworth, RD | 1 |
| Adams, CM | 1 |
| Middleton, JE | 1 |
| Goodland, FC | 1 |
| Nash, DT | 1 |
| Fujii, S | 1 |
| Sawa, H | 1 |
| Sobel, BE | 1 |
| Spence, JD | 1 |
| Munoz, CE | 1 |
| Hendricks, L | 1 |
| Latchinian, L | 1 |
| Khouri, HE | 1 |
| Schonfeld, G | 1 |
| Knipscheer, HC | 1 |
| Nurmohamed, MT | 1 |
| Van den Ende, A | 1 |
| Plaat, B | 1 |
| Pruijs, HJ | 1 |
| Mulder, WJ | 1 |
| Kastelein, JJ | 1 |
| Kuo, PT | 1 |
| Vartanova, OA | 1 |
| Aleksandrovskaia, TN | 1 |
| Shaldaeva, VV | 1 |
| Vuorinen-Markkola, H | 1 |
| Hilden, H | 1 |
| Jogestrand, T | 1 |
| Fehrman-Ekholm, I | 1 |
| Angelin, B | 1 |
| Berglund, L | 1 |
| Gäbel, H | 1 |
| Kauma, H | 1 |
| Majahalme, S | 1 |
| Virtanen, V | 1 |
| Kesten, S | 1 |
| Mayne, L | 1 |
| Scavuzzo, M | 1 |
| Maurer, J | 1 |
| Liu, R | 1 |
| Saku, K | 1 |
| Jimi, S | 1 |
| Ohta, T | 1 |
| Zhang, B | 1 |
| Takebayashi, S | 1 |
| Arakawa, K | 1 |
| Migdalis, IN | 1 |
| Gerolimou, B | 1 |
| Kozanidou, G | 1 |
| Voudouris, G | 1 |
| Hatzigakis, SM | 1 |
| Petropoulos, A | 1 |
| Bhandari, U | 1 |
| Sharma, JN | 1 |
| Zafar, R | 1 |
| Yoshida, H | 1 |
| Ishikawa, T | 1 |
| Ayaori, M | 1 |
| Shige, H | 1 |
| Ito, T | 1 |
| Suzukawa, M | 1 |
| Nakamura, H | 1 |
| Sinzinger, H | 1 |
| Zema, MJ | 1 |
| Royo, T | 1 |
| Alfón, J | 1 |
| Berrozpe, M | 1 |
| Badimon, L | 1 |
| Stein, EA | 1 |
| Paragh, G | 1 |
| Harangi, M | 1 |
| Tada, N | 1 |
| Steinmetz, A | 1 |
| Fenselau, S | 1 |
| Schrezenmeir, J | 1 |
| Avogaro, A | 1 |
| Miola, M | 1 |
| Favaro, A | 1 |
| Gottardo, L | 1 |
| Pacini, G | 1 |
| Manzato, E | 1 |
| Zambon, S | 1 |
| Sacerdoti, D | 1 |
| de Kreutzenberg, S | 1 |
| Piliego, T | 1 |
| Tiengo, A | 1 |
| Del Prato, S | 1 |
| Marx, N | 1 |
| Hombach, V | 1 |
| Sakai, T | 1 |
| Kamanna, VS | 1 |
| Kashyap, ML | 1 |
| Flavell, DM | 1 |
| Jamshidi, Y | 1 |
| Hawe, E | 1 |
| Pineda Torra, I | 1 |
| Staels, B | 1 |
| Miller, G | 1 |
| Wierzbicki, AS | 1 |
| Mikhailidis, DP | 1 |
| Steiner, G | 1 |
| Glueck, CJ | 2 |
| Speirs, J | 1 |
| Tracy, T | 1 |
| Kremer, P | 1 |
| Marowski, C | 1 |
| Jones, C | 1 |
| Acacia, E | 1 |
| Kane, JP | 1 |
| Malloy, MJ | 1 |
| Davignon, J | 1 |
| Oliver, MF | 1 |
11 reviews available for gemfibrozil and Arteriosclerosis
| Article | Year |
|---|---|
Patients with low levels of high-density lipoprotein cholesterol: to treat or not to treat?
Topics: Apoproteins; Arteriosclerosis; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, H | 2005 |
[Pharmacologic therapy of atherosclerosis (I). Current possibilities].
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Clofibrate; Clofibric Acid; Fenofibrate; Ge | 1983 |
The effects of fibrates on lipoprotein and hemostatic coronary risk factors.
Topics: Arteriosclerosis; Bezafibrate; Blood Coagulation; Clofibric Acid; Coronary Disease; Fenofibrate; Fib | 1994 |
Dyslipidemia and coronary artery disease.
Topics: Arteriosclerosis; Cholesterol; Coronary Disease; Drug Therapy, Combination; Exercise; Gemfibrozil; H | 1994 |
[Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis].
Topics: Anticholesteremic Agents; Antiporters; Arteriosclerosis; Bezafibrate; Blood Coagulation; Blood Coagu | 1998 |
[The role of HDL in the prevention of cardiovascular events].
Topics: Anticholesteremic Agents; Arteriosclerosis; Aryldialkylphosphatase; Atorvastatin; Cholesterol, HDL; | 2001 |
[Gemfibrozil: new aspects in clinical use].
Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Gemfibrozil; Humans; Hyperli | 2001 |
Treatment of dyslipoproteinemia in the metabolic syndrome.
Topics: Arteriosclerosis; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Gemfibrozil; Humans; | 2001 |
[Peroxisome proliferator-activated receptors (PPARs) in the vessel wall: new regulators of gene expression in vascular cells].
Topics: Animals; Arteriosclerosis; Chromans; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, | 2001 |
Beyond LDL-C--the importance of raising HDL-C.
Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Gemfibrozil; Humans; Hydroxy | 2002 |
When to treat hyperlipidemia.
Topics: Animals; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; H | 1988 |
15 trials available for gemfibrozil and Arteriosclerosis
| Article | Year |
|---|---|
A pilot study of the effect of Gemfibrozil on some haematological parameters.
Topics: Aged; Arteriosclerosis; Blood Coagulation Tests; Cholesterol; Cholesterol, HDL; Female; Gemfibrozil; | 1982 |
Hyperlipoproteinemia, atherosclerosis and gemfibrozil.
Topics: Adult; Aged; Arteriosclerosis; Cholesterol; Female; Gemfibrozil; Humans; Hyperlipoproteinemias; Hypo | 1982 |
Pharmacokinetics of the combination of fluvastatin and gemfibrozil.
Topics: Anticholesteremic Agents; Arteriosclerosis; Carotid Stenosis; Coronary Artery Disease; Coronary Dise | 1995 |
Gemfibrozil treatment of the high triglyceride-low high-density lipoprotein cholesterol trait in men with established atherosclerosis.
Topics: Adult; Aged; Arteriosclerosis; Cholesterol, HDL; Double-Blind Method; Gemfibrozil; Humans; Hypertrig | 1994 |
Gemfibrozil reduces postprandial lipemia in non-insulin-dependent diabetes mellitus.
Topics: Arteriosclerosis; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diterpenes; Female; Food; Gemfibrozil | 1993 |
Increased prevalence of atherosclerotic wall changes in patients with hyperlipidaemia after renal transplantation.
Topics: Adult; Arteriosclerosis; Carotid Artery, Common; Double-Blind Method; Female; Gemfibrozil; Humans; H | 1996 |
Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group.
Topics: Aged; Analysis of Variance; Arteriosclerosis; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coron | 1997 |
Effect of gemfibrozil on early carotid atherosclerosis in diabetic patients with hyperlipidaemia.
Topics: Administration, Oral; Arteriosclerosis; Blood Glucose; Carotid Artery Diseases; Carotid Artery, Comm | 1997 |
Beneficial effect of gemfibrozil on the chemical composition and oxidative susceptibility of low density lipoprotein: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Apolipoproteins; Arteriosclerosis; Double-Blind Method; Fatty Acids, Nonesterified; Fem | 1998 |
Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Stu | 2000 |
Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients.
Topics: Aged; Arteriosclerosis; Blood Circulation; Diabetes Mellitus, Type 2; Endothelium, Vascular; Gemfibr | 2001 |
Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol.
Topics: Apolipoprotein A-I; Apolipoprotein A-II; Arteriosclerosis; Cholesterol, HDL; Dose-Response Relations | 2001 |
Altering triglyceride concentrations changes insulin-glucose relationships in hypertriglyceridemic patients. Double-blind study with gemfibrozil with implications for atherosclerosis.
Topics: Arteriosclerosis; Blood Glucose; Double-Blind Method; Female; Gemfibrozil; Glucose Tolerance Test; H | 1991 |
Therapeutic effects of bezafibrate and gemfibrozil in hyperlipoproteinaemia type IIa and IIb.
Topics: Adult; Aged; Argentina; Arteriosclerosis; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; | 1989 |
Strategy, yield and risks of controlling plasma lipids in the primary prevention of coronary heart disease.
Topics: Adult; Arteriosclerosis; Cholesterol; Clinical Trials as Topic; Clofibrate; Coronary Disease; Diet; | 1985 |
13 other studies available for gemfibrozil and Arteriosclerosis
| Article | Year |
|---|---|
APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study.
Topics: Aged; Apolipoprotein A-V; Apolipoproteins; Apolipoproteins A; Arteriosclerosis; Coronary Disease; Di | 2004 |
Inhibition of endothelial cell expression of plasminogen activator inhibitor type-1 by gemfibrozil.
Topics: Animals; Arteriosclerosis; Blood Proteins; Carcinoma, Hepatocellular; Cells, Cultured; Endothelium, | 1993 |
[Gemfibrozil in the treatment of lipid metabolism disorders].
Topics: Adult; Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Exercise Test; Femal | 1994 |
Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Echocardiography; Fem | 1997 |
Mechanism of action of gemfibrozil on HDL metabolism and atherosclerosis in WHHL rabbits.
Topics: Animals; Aorta, Thoracic; Apolipoprotein A-I; Arteriosclerosis; Gemfibrozil; Hypolipidemic Agents; L | 1997 |
The protective action of ethanolic ginger (Zingiber officinale) extract in cholesterol fed rabbits.
Topics: Animals; Anticholesteremic Agents; Aorta, Thoracic; Arteriosclerosis; Cholesterol, Dietary; Gemfibro | 1998 |
Effect of gemfibrozil on peripheral atherosclerosis and platelet activation in a pig model of hyperlipidemia.
Topics: Animals; Antibodies; Aorta, Abdominal; Arteriosclerosis; Blood Platelets; Cholesterol; Disease Model | 2000 |
Lipid modulation and atherosclerotic events: extending the clinical spectrum with fibrates and statins.
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Evi | 2000 |
Choice of lipid-regulating drugs.
Topics: Apolipoproteins; Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Intera | 2001 |
Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease.
Topics: Aged; Alleles; Amino Acid Substitution; Arteriosclerosis; Clinical Trials as Topic; Cohort Studies; | 2002 |
Safety and efficacy of combined gemfibrozil-lovastatin therapy for primary dyslipoproteinemias.
Topics: Adult; Aged; Arteriosclerosis; Cholesterol; Drug Therapy, Combination; Female; Gemfibrozil; Humans; | 1990 |
Nonpharmacologic and pharmacologic alteration of high-density lipoprotein cholesterol: therapeutic approaches to prevention of atherosclerosis.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Arteriosclerosis; Body Weight; Cholesterol, H | 1985 |
Medical management of hyperlipidemia and the role of probucol.
Topics: Adult; Arteriosclerosis; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Female; Gem | 1986 |